Search | Page 15 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MDS - Treatment (OLD)

    ... (Dacogen®), both considered hypomethylating agents, and lenalidomide (Revlimid®), which is considered an immunomodulatry agent. ...

    Topic section last updated 03/10/2016 - 11:01pm.

  2. MDS Drug Information

    ... N eupogen lenalidomide R evlimid ...

    Page last updated 01/20/2015 - 4:46pm.

  3. Nursing Education Modules on MDS Disease Management and Patient Education

    ... Treatment options for low-risk MDS – observation, EPO, lenalidomide , immune suppression,       iron chelation Treatment ...

    Page last updated 04/27/2015 - 2:44pm.

  4. Nurse's Corner Summer 2015: Understanding the Etiology and Epidemiology of Myelodysplastic Syndromes

    ... Available options include erythroid stimulating agents, lenalidomide for patients with deletion 5 q MDS, hypomethylating agents and ...

    Page last updated 07/27/2015 - 12:04pm.

  5. Patient Education Materials

    ... (Vidaza®), decitabine (Dacogen®) and lenalidomide (Revlimid®). Read about how what to know before starting ...

    Page last updated 11/06/2013 - 4:28pm.

  6. Aristoteles Giagounidis, MD

    ... breaking, new therapeutic approaches. These include lenalidomide and azacitidine in myelodysplastic syndromes, ...

    Page last updated 01/20/2012 - 3:30pm.

  7. Scientific Symposium Co-Chair Richard Stone, MD Discusses Progress and New Directions in Bone Marrow Failure Disease Research

    ... report at the meeting from Dr. Benjamin Ebert about how lenalidomide might work to effect on ubiquitin ligase and the ability to ...

    Interview last updated 04/29/2014 - 12:01pm.

  8. Research Overview - Recent Past Progress and Projections for the Near-Term

    ... that takes you back to further science basic research. Lenalidomide is a good example of this. In the laboratory, we saw it ... to find out what are the targets in deletion 5q that allowed lenalidomide to suppress the clone. Later, as patients failed lenalidomide, we ...

    Interview last updated 02/10/2014 - 9:40am.

  9. Research Overview – Recent Past Progress and Projections for the Near-Term

    ... have a discovery that takes you back to basic research.  Lenalidomide is a good example of this –in the laboratory we saw it affected ... to suppress the clone. Then when patients failed lenalidomide , we went back and studied the mechanism for resistance to the ...

    Page last updated 01/14/2014 - 11:47am.

  10. What MDS Patients Should Know About Clinical Trials

    ... approved drugs available for people with MDS. These are lenalidomide (Revlimid®), azacitidine (Vidaza®), and ... MDS -- received either azacitidine alone, azacitidine and lenalidomide, or azacitidine combined with vorinostat.  I wrote this study ...

    Interview last updated 11/13/2015 - 11:12am.